Rationale for Correct Answer

The correct answer is: In phase 3 placebo-controlled trials, ozanimod was an effective treatment for UC

In phase 3 placebo-controlled trials, both ozanimod1 and etrasimod2 were effective treatments for UC. A phase 3 trial for ozanimod in CD is currently underway.3 In the safety analyses, the rates of cancer, serious and opportunistic infections, and macular edema were low and similar to placebo.1,2 Almost half of those in the treatment groups, however, had reduced lymphocyte levels,1,2 and liver dysfunction was observed with ozanimod.1 Cardiac heart rate or conduction aberrations that occurred were associated with the first dose.1,2

1. Sandborn WJ et al. N Engl J Med. 2021;385(14):1280-91;
2. Sandborn WJ et al. Lancet. 2023;401(10383):1159-71;
3. Clinicaltrials.gov. NCT03464097.